Participated · Series A · Feb 2026

Avisi Technologies, Inc. is a clinical-stage company focused on creating novel ophthalmic solutions, most notably VisiPlate®, an investigational aqueous shunt engineered from an ultrathin, patented metamaterial designed to maintain intra-ocular pressure through multiple microchannels that resist blockage and scarring. The device targets the unmet need for long-term, low-maintenance glaucoma care and is currently being evaluated in the FDA IDE-approved SAPPHIRE pivotal trial that is enrolling patients across the United States. Avisi’s broader pipeline includes V-001, a sustained intraocular drug-delivery platform, and VisiPlate-S, a drainage device intended for use during cataract surgery. Proceeds from its latest financing will fund the SAPPHIRE trial and advance additional pipeline programs addressing the full spectrum of glaucomatous disease. The company has garnered recognition and non-dilutive support from the National Science Foundation, the Glaucoma Research Foundation, Johnson & Johnson JLABS, and other industry accelerators. Current investors include both venture funds and angel networks, underscoring diversified backing for its development roadmap. No revenue or user figures have been disclosed to date.

Participated · Seed · Feb 2026

Founded in 2021 out of Princeton University, PolyGone Systems develops patented filtration systems that remove 98% of toxic microplastics from water at 90% lower cost than existing alternatives. Its flagship PolyPod™ units are engineered to treat up to 10 million gallons of water per day, targeting municipal wastewater facilities. Complementing the hardware, the company has launched a microplastics analysis service that provides affordable testing for public agencies, private companies, and utilities to assess contamination and regulatory compliance. PolyGone is currently running a wastewater pilot with the Atlantic County Utilities Authority and has signed three additional commercial deployments slated for 2026 across municipal, industrial, and food-and-beverage customers. Near-term plans include mass production of the PolyPod™ systems and the release of an inline PolyCartridge™ filter for industrial water streams. Management positions the company as a future proprietary data and intelligence provider on microplastic pollution, aiming to become indispensable to water authorities and industrial operators. No revenue figures were disclosed in the articles.

Participated · Seed · Aug 2025

Nullspace develops enterprise electromagnetic simulation software aimed at accelerating design for RF systems and quantum computing hardware. Its flagship Nullspace EM targets fast, full-fidelity simulation of large, complex RF designs, while Nullspace ES is positioned for design and analysis of extremely large ion traps. The company intends to use new funding to expand the engineering team, accelerate product development, and scale go-to-market efforts across aerospace, defense, quantum computing, and AI-enabled hardware markets. Nullspace traces its core solver technology to more than a decade of development through IERUS Technologies and says that technology has been tested on real-world antenna, microwave, scattering, and ion-trap design problems, including physical products delivered to the U.S. Department of Defense. Fathom Fund’s managing partner Paul Sheng will join the board, and Dr. Nathan Kundtz will join as an independent board director. The company is based in Huntsville, Ala., and is led by co-founders Dr. Masha Petrova (CEO) and Dr. Daniel Faircloth (CTO).

Participated · Series A · Jul 2025

Cooler Heads develops Amma™, which the company describes as the only FDA‑cleared portable scalp cooling system, designed to help chemotherapy patients keep their hair and preserve privacy. Amma provides infusion centers and patients flexibility to scalp cool where it is most convenient, using a continuous cooling system that eliminates the need for dry ice or frequent cap changes. By cooling the scalp before, during, and after chemotherapy, Amma reduces blood flow to hair follicles to shield them from chemotherapy drugs and prevent hair loss. The company was founded by breast cancer survivor Kate Dilligan, who serves as CEO. Cooler Heads positions Amma as a low‑friction therapy for infusion centers and notes the American Medical Association’s decision to elevate scalp cooling reimbursement codes to Category I starting January 2026 as creating momentum. The business also offers evidence‑based products, content, and services to help patients manage treatment side effects. Cooler Heads develops Amma, an FDA-cleared scalp-cooling medical device intended to help cancer patients undergoing chemotherapy preserve their hair. The company positions its product as dramatically less expensive and easier to use than existing scalp-cooling solutions. Founder and CEO Kate Dilligan, a cancer survivor, built an early prototype herself and pursued clinical relationships before raising institutional capital. Cooler Heads announced FDA clearance and said it has signed multiple commercial partnerships and will begin serving patients in Q1 2022. The company highlighted its mission-driven focus on patient dignity and plans to push commercialization to make scalp cooling broadly accessible. Cooler Heads has been backed by several venture investors and industry leaders and has participated in accelerators and medtech competitions.

Participated · Equity · Jul 2025

Oh Norman! is a pet wellness brand co-founded by Kaley Cuoco and Katie Hunt that launched in 2023 to modernize how pet parents support dogs' emotional and physical health. Its core product is the best-selling calming supplement Calm the Eff Down!, and the company emphasizes high-quality ingredients and data-driven outcomes. The brand has expanded distribution through retail partnerships and direct channels, including a partnership with Chewy announced in April 2025 to increase accessibility. Oh Norman! operates a six-person, all-female team and has grown its social media following to over 250K followers. Financially, the company has raised a total of over $5 million to date, including the $2.08 million round announced in July 2025. Management says it will use the new capital to accelerate product development and continue delivering science-backed, ethical, and eco-conscious pet wellness products.